ReaMetrix Inc. 2385 Bering Drive San Jose, CA 95131USA Phone : +1 650 620 9253 Fax : +1 650 620 0093 email@example.com
ReaMetrix India Pvt. Ltd. # 411 Block IV, Shobha Orchid, Jakkur Village, Yalahanka, Bangalore 560 064,Karnataka, India. Phone: +918023624777 firstname.lastname@example.org
Mazumdar Shaw Center for Translational Research, Wing-A, 8th floor, Mazumdar Shaw Cancer Center, Narayana Hrudayalaya Health City, 258/A Bommasandra Industrial Area, Anekal Taluk, Bangalore 560 099,Karnataka, India. Phone : +918027803456 Ext. 2748 email@example.com
Bala S. Manian
Dr. Manian has been a distinguished contributor to the Silicon Valley entrepreneurial community for the last three decades. At present Dr. Manian is focused on ReaMetrix, which he founded in May of 2003. ReaMetrix is committed to becoming the leading provider of easy-to-use assay solutions that increase reliability and consistency, expand the capabilities of proprietary technology platforms, increase the experimental efficiency and at the same time bring affordable solutions to address needs in India and other developing nations. Dr. Manian is a co-founder and director of Quantum Dot Corporation, and a co-founder of SurroMed Corporation, both of which are privately held. He was the founder and Chairman of Biometric Imaging, Inc. which was acquired by Becton Dickinson in February 1999. Prior to founding Biometric Imaging, Inc., Dr. Manian founded both Lumisys and Molecular Dynamics in June 1987 and was their founder chairman and CTO. Lumisys went public in 1995 and later was acquired by Eastman Kodak in December of 2000. Molecular Dynamics went public in 1993, and subsequently was acquired by Amersham in 1998. Dr. Manian founded Digital Optics Corporation in 1980, an optical instrumentation and systems development Company that was acquired by the publicly traded Matrix Corporation in 1984.
Steve has been a member of the research and development team at ReaMetrix since 2004. From 1998-2003, Steve was director of life science at Arcturus Bioscience, where he developed Arcturus’ “Platform for microgenomics,” a reagent system preparing microdissected samples for expression analysis. Steve was a senior scientist at Biometric Imaging from 1994-1998, while it was developing a number of cell based assays for the IMAGN system. Prior to that, Steve served as a research scientist in the Atherosclerosis group at the University of California, San Francisco. Steve Kunitake received his Ph. D. in Biochemistry from the University of California at Los Angeles.
Zaki N Manian
Zaki leads the software development and overall system integration of ReaMetrix's instrument platforms. Zaki has been working with ReaMetrix since 2007 on both internal software systems and instrument design. He graduated from University of Pennsylvania in 2005 with a BA degree in the History and Sociology of Science. He is a software developement autodidact whose interests include embedded systems, image analysis and functional programming.
Prabhakar is an innovator with entrepreneurial zeal working with ReaMetrix since 2010, focused towards 'bringing small changes' in the way diagnostic assay is carried out to 'make a big difference' in the reliability of the process. He is PhD in Nano-biotechnology with vast experience in technology development through life science research. He has won numerous awards and accolades for technology development in in India and abroad. In last two years he has made significant contribution towards product development in tuberculosis diagnosis as a scientist and product evangelist, both in product development and evaluation of market for product positioning. He is an artist specialized in painting, sculpture, paper craft.
ReaMetrix, Inc. is a next generation biotechnology company with its primary operations centered in India focused on creating affordable diagnostics.It is utilizing the challenge of developing innovative affordable solutions that meet global standards, as a driver to break the rules of conventional thinking. It conceives, creates and validates solutions at the 'point of use' to impact the entire innovation process.With such an approach, ReaMetrix strongly believes that it can not just address the emerging needs of the developing world but can have a paradigm changing impact on global healthcare delivery.
Conventional thinking views diagnostics as fusion of measurement technology platform and assay reagent consumables. Hence, when one addresses the unmet needs of the developing economies, the focus has always been on the development of new and different technologies to reduce the cost of the hardware, improve method of delivery away from a centralized lab or package the reagents differently to enhance affordability. However, one has to view diagnostics as an information-generation activity. Under optimal conditions, relevant information is generated in the most cost-effective manner and delivered promptly to help the physician better manage the patient. Therefore what is important is not just the cost of the hardware – assay reagent combination but the overall cost of generating that information. ReaMetrix set out to address this problem in a holistic manner capturing all the costs involved. This approach to framing the problem has allowed ReaMetrix to develop, a revolutionary new systems platform involving hardware, software, sample delivery, and reagent delivery. The resulting solution is capable of fundamentally changing not just the economics but also the nature of the delivery of the diagnostics information closer to the point of physician – patient interaction.
IMMEDIA System platform is an in-vitro diagnostics platform based new approach to detection that spans across multiple types of sample, multiple assay formats and multiple disciplines of diagnostic information. This technology represents the convergence of cross-disciplinary innovations involving laser optics, opto-mechanical movements, micro-fluidics, high sensitivity detection electronics, data processing and unique assay reagents that are dry & unitized. In particular, the unique assay reagents have enabled ReaMetrix to convert traditional absorbance based measurements & methodologies into high sensitivity fluorescence measurements in NIR region impacting the sample preparation, the volume of sample required, the material used for the consumable and the nature of the delivery of the assay. What started out as an attempt to generate a cost effective solution for resource poor settings, has now evolved into a “first of its kind” versatile system platform capable of performing complex high sensitivity assays in Clinical chemistry/biochemistry, Immunology, Clinical microbiology and Immuno-cytometry in an easy to use point of care format that has global impact.